Amgen P/E Adelante
¿Qué es el P/E Adelante de Amgen?
El P/E Adelante de Amgen, Inc. es 15.20
¿Cuál es la definición de P/E Adelante?
La relación precio a futuro es la relación entre el precio de las acciones de una empresa y las ganancias por acción estimadas de la compañía para los próximos doce meses.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
P/E Adelante de compañías en Sector Health Care en XETRA en comparadas con Amgen
¿Qué hace Amgen?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Empresas con p/e adelante similar a Amgen
- Premium Brands tiene P/E Adelante de 15.17
- Boiron SA tiene P/E Adelante de 15.17
- Mirvac Stapled Securities tiene P/E Adelante de 15.17
- Rank Plc tiene P/E Adelante de 15.17
- Assured Guaranty Ltd tiene P/E Adelante de 15.18
- Canadian National Railway Co tiene P/E Adelante de 15.18
- Amgen tiene P/E Adelante de 15.20
- Texas Pacific Land tiene P/E Adelante de 15.22
- Indoco Remedies tiene P/E Adelante de 15.22
- Evolution Mining tiene P/E Adelante de 15.22
- Parker-Hannifin tiene P/E Adelante de 15.22
- Ashtead Plc tiene P/E Adelante de 15.22
- Iberdrola SA tiene P/E Adelante de 15.22